Nanchang, China – On April 26 to 28, the 22nd Edition of China Cardiovascular Intervention Forum (CCIF 2019) was held here, bringing together many cardiologists from both China and abroad to discuss the new development, new results and new experience in the cardiovascular field. Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) took part in CCIF 2019 and sponsored a case competition named List of Langya.
On April 27, the case competition took place with the theme of “Challenging Diseases, Complex Lesions” during CCIF 2019, with 12 outstanding cases selected from across China. The cases were reviewed by a panel comprising renowned Chinese physicians including Prof. Jinghua Liu from Beijing Anzhen Hospital of Capital Medical University, Prof. Yan Li from Xijing Hospital of Air Force Medical University, Prof. Lixia Yang from Chinese PLA 902 Hospital, and Prof. Yanqing Wu from the Second Affiliated Hospital of Nanchang University. Prof. Jun Liu from Xiangya Hospital, Central South University and Prof. Qing He from Shanghai Ninth People’s Hospital ended up winning the top prize. Throughout the case competition, the physicians had continual and heated discussions and exchanges on their clinical experience in the handling of challenging diseases.
MicroPort® has been sponsoring the case competition since 2016 and received favorable comments at several well-known domestic symposiums. The case competition at CCIF2019 marked the fourth to be held during the event to fully demonstrate the outstanding clinical performance of the MicroPort® coronary artery stent products with top physicians’ discussions on specific topics and perspectives. Prof. Yan Li from Xijing Hospital of Air Force Medical University commented that the case competition had established itself as a brand campaign of MicroPort®, as every edition of it had provided highly valuable expertise for the physicians to learn, making the case completion worth following for the interventional cardiologists.
During the CCIF 2019, Prof. Yong Huo, who is deputy chairman of China Cardiovascular Association and from Peking University First Hospital, released on behalf of National Cardiovascular Disease Healthcare Quality Control Center the widely watched statistics on China’s PCI treatment of coronary artery diseases in 2018. Since 2009, the annual releases of the statistics have not only presented the number of China’s PCI treatment of coronary artery diseases, but also been a public inspection of the quality of PCI treatment in China. The statistics showed that a total of 915,256 cases of PCI treatment were performed nationwide in 2018, with a year-over-year growth of over 20%. Prof. Yong Huo said that China’s PCI treatment of coronary artery diseases had been improving in a steady development in terms of both quantity and quality. The number of implanted stents averaged 1.46 per case in 2018, extending a downward trend since in 2011. The figure held steady around 1.5 per case on average in recent years, which revealed relatively reasonable therapeutic indications of PCI treatment and stent applications. The radial artery access continued to be an overwhelmingly major vascular access, accounting for 90.65% of total cases. Meanwhile, the overall fatality rate for PCI treatment held steady at a relatively low level.
In addition, the proportion of the ST-Elevation Myocardial Infarction (STEMI) receiving emergency PCI treatment posted a further increase, which demonstrated that the building of Chest Pain Centers has achieved excellent results in China. The PCI competency has also gradually improved at the Chinese district and county-level hospitals and privately-run hospitals, which have been playing an increasingly important part in the treatment of coronary artery diseases. Prof. Yong Huo added that in the future, China should not only focus on its developed regions’ catching up with the advanced international standard to narrow the gap in cardiology, but pay more attention to meeting the clinical needs from the clinicians at various levels in the developing regions to promote the development of China’s interventional cardiology.